Abstract | INTRODUCTION: MATERIAL AND METHODS: RESULTS:
Carbonate buffer was the best conjugation buffer (number of chelates per antibody: 6; incorporated activity: 81%; immunoreactivity: 87%; buffer stability: 86%; serum stability: 81%, after 4 days). The efficient tumor uptake observed in the biodistribution studies was consistent with the gamma camera image results. At a concentration of 4 μg ml(-1), (177)Lu-Herceptin (surviving cells: 5 ± 0.6% of the total cells) of the total cells corresponded to an approximately eightfold increase in cytotoxicity in comparison to unmodified Herceptin (surviving cells: 43 ± 3.9%). CONCLUSION: The new complex described herein could be considered for further evaluation in animals and potentially in humans as a radiopharmaceutical for use in the radioimmunotherapy of breast cancer. These results may be important for patients who cannot tolerate the therapeutic dosage of Herceptin currently used because of heart problems.
|
Authors | Samira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, Fariba Johari Daha |
Journal | Nuclear medicine and biology
(Nucl Med Biol)
Vol. 37
Issue 8
Pg. 949-55
(Nov 2010)
ISSN: 1872-9614 [Electronic] United States |
PMID | 21055626
(Publication Type: Journal Article, Validation Study)
|
Copyright | Copyright © 2010. Published by Elsevier Inc. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Radioisotopes
- Radiopharmaceuticals
- Lutetium
- Trastuzumab
|
Topics |
- Animals
- Antibodies, Monoclonal
(pharmacokinetics, pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms
(diagnostic imaging, pathology, radiotherapy)
- Cell Line, Tumor
- Drug Evaluation, Preclinical
- Female
- Lutetium
(therapeutic use)
- Mice
- Quality Control
- Radioimmunotherapy
(methods)
- Radioisotopes
(therapeutic use)
- Radionuclide Imaging
- Radiopharmaceuticals
(pharmacokinetics, pharmacology, therapeutic use)
- Reproducibility of Results
- Trastuzumab
|